Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo sinh học: " Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication | Virology Journal BioMed Central Research Open Access Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication Haizhen Zhu1 Mike Butera1 David R Nelson2 and Chen Liu 1 Address department of Pathology Immunology and Laboratory Medicine University of Florida P. O. Box 100275 Gainesville Florida 32610 USA and department of Medicine University of Florida P. O. Box 100275 Gainesville Florida 32610 USA Email Haizhen Zhu - zhu@pathology.ufl.edu Mike Butera - butera@pathology.ufl.edu David R Nelson - Nelsond@medicine.ufl.edu Chen Liu - liu@pathology.ufl.edu Corresponding author Published 07 September 2005 Received 06 June 2005 Accepted 07 September 2005 Virology Journal 2005 2 80 doi 10.1186 1743-422X-2-80 This article is available from http www.virologyj.com content 2 1 80 2005 Zhu et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.Org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Interferon alpha IFN-a -based therapy is the currently approved treatment for chronic hepatitis C viral infection. The sustained antiviral response rate is approximately 50 for genotype-1 infection. The major challenge to the HCV community is to improve antiviral efficacy and to reduce the side effects typically seen in IFNa-based therapy. One of the strategies is to identify new interferons which may have better efficacy and less undesirable side effects. In this report we examined the role of IL-28A IFN À.2 a novel type I IFN in suppression of human hepatitis C viral RNA replication. We have cloned both the human genomic DNA and cDNA of IL-28A and evaluated their biological activity using HCV RNA replicon cell culture system. The results show that IL-28A effectively inhibits HCV subgenomic RNA replication in a dose-dependent manner. Treatment of human hepatoma cells with